In 2016, Tap et al. published the surprising results of a phase Ib/II randomized open label study in advanced STS, comparing doxorubicin monotherapy with doxorubicin and the anti-PDGFRA monoclonal antibody olaratumab [19]. This evidence concerns the gene PDGFRA and telomere syndrome.